Application of nanofiltration for the removal of carbamazepine, diclofenac and ibuprofen from drinking water sources

Journal of Environmental Management

Volumn 127, Issue , 2013, Pages 177-187

  Vergili, I ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Drinking water source; FT IR; Nanofiltration; Pharmaceutical active compounds

Indexed keywords

CALCIUM SALT; CARBAMAZEPINE; DICLOFENAC; DRINKING WATER; IBUPROFEN; SURFACE WATER;

ADSORPTION; CALCIUM; DRINKING WATER; DRUG; FTIR SPECTROSCOPY; MEMBRANE; NANOTECHNOLOGY; POLLUTANT REMOVAL; SURFACE WATER; ULTRAFILTRATION; WATER RESOURCE; WATER TREATMENT;

ARTICLE; ARTIFICIAL MEMBRANE; CROSSFLOW FILTRATION; DRUG SOLUBILITY; ELECTRICITY; INFRARED SPECTROMETRY; MOLECULAR SIZE; NANOFILTRATION; WASTE COMPONENT REMOVAL; WASTE WATER TREATMENT PLANT; WATER SUPPLY;

EID: 84878359686     PISSN: 03014797     EISSN: 10958630     Source Type: Journal    
DOI: 10.1016/j.jenvman.2013.04.036     Document Type: Article

References (59)

1. Adham S., Chiu K.P., Lehman G., Mysore C., Clouet J. Optimization of Membrane Treatment for Direct and Clarified Water Filtration 2006, American Water Works Association, USA.
2. 2/UV-A processes. Water Res. 2002, 36:1143-1154.
3. Al-Rashdi B.A.M., Johnson D.J., Hilal N. Removal of heavy metal ions by nanofiltration. Desalination 2012, 315:2-17.
4. Amy G., Kim T.U., Yoon J., Bellona C., Drewes J., Pellegrino J., Heberer T. Removal of micropollutants by NF/RO membranes. Water Supply 2005, 5:25-33.
5. APHA/AWWA/WEF Standard Methods for the Examination of Water and Wastewater 1995, American Public Health Association, Washington DC.
6. Arkhangelsky E., Kuzmenko D., Gitis V. Impact of chemical cleaning on properties and functioning of polyethersulfone membranes. J.Membr. Sci. 2007, 305:176-184.
7. Aydiner C., Kaya Y., Gönder Z.B., Vergili I. Evaluation of membrane fouling and flux decline related with mass transport in nanofiltration of tartrazine solution. J.Chem. Technol. Biotechnol. 2010, 85:1229-1240.
8. Bartels C., Franks R., Rybar S., Schierach M., Wilf M. The effect of feed ionic strength on salt passage through reverse osmosis membranes. Desalination 2005, 184:185-195.
9. Belfer S., Fainchtain R., Purinson Y., Kedem O. Surface characterization by FTIR-ATR spectroscopy of polyethersulfone membranes - unmodified, modified and protein fouled. J.Membr. Sci. 2000, 172:13-124.
10. Bellona C., Drewes J.E., Xu P., Amy G. Factors affecting the rejection of organic solutes during NF/RO treatment - a literature review. Water Res. 2004, 38:2795-2809.
11. Bellona C., Drewes J.E. The role of physico-chemical properties of membranes and solutes in the rejection of organic acids by nanofiltration membranes. J.Membr. Sci. 2005, 249:227-234.
12. Beltran F.J., Pocostales P., Alvareza P., Oropesab A. Diclofenac removal from water with ozone and activated carbon. J.Hazard. Mater. 2009, 163:768-776.
13. Benitez F.J., Acero J.L., Real F.J., Roldán G., Rodriguez E. Ultrafiltration and nanofiltration membranes applied to the removal of the pharmaceuticals amoxicillin, naproxen, metoprolol and phenacetin from water. J.Chem. Technol. Biotechnol. 2011, 86:858-866.
14. Bormashenko Y., Pogreb R., Stanevsky O., Bormashenko E. Vibrational spectrum of PVDF and its interpretation. Polym. Test. 2004, 23:791-796.
15. Boussu K., Vandecasteele C., Van der Bruggen B. Study of characteristic and the performance of self-made nanoporous polyethersulfone membranes. Polymer 2006, 47:3464-3476.
16. Dai C.M., Geissen S.U., Zhang Y.L., Zhang Y.J., Zhou X.F. Selective removal of diclofenac from contaminated water using molecularly imprinted polymer microspheres. Environ. Pollut. 2011, 159:1660-1666.
17. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environ. Health. Perspect. 1999, 107(Suppl.):907-938.
18. Dean J.A. Lange's Handbook of Chemistry 1999, McGraw-Hill, New York. fifteenth ed.
19. Deegan A.M., Shaik B., Nolan K., Urell K., Oelgemöller M., Tobin J., Morrissey A. Treatment options for wastewater effluents from pharmaceutical companies. Int. J. Environ. Sci. Te 2011, 8:649-666.
20. Doulia D., Xiarchos I. Ultrafiltration of micellar solutions of nonionic surfactants with or without alachlor pesticide. J.Membr. Sci. 2007, 296:58-64.
21. Heberer T. Occurrence, fate and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol. Lett. 2002, 131:5-17.
22. Hilton M.J., Thomas K.V. Determination of selected human pharmaceutical compounds in effluent and surface water samples by high-performance liquid chromatography-electrospray tandem mass spectrometry. J.Chromatogr. A 2003, 1015:129-141.
23. Huber M.M., Canonica S., Park G.Y., Von Gunten U. Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. Environ. Sci. Technol. 2003, 37:1016-1024.
24. Kiso Y., Kon T., Kitao T., Nishimura K. Rejection properties of alkyl phthalates with nanofiltration membranes. J.Memb. Sci. 2001, 182:205-214.
25. Laville N., Ait-Aissa S., Gomez E., Casellas C., Porcher J.M. Effects of human pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes. Toxicology 2004, 196:41-55.
26. Mompelat S., Le Bot B., Thomas O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. Environ. Int. 2009, 35:803-814.
27. Nghiem L.D., Schäfer A.I., Elimelech M. Removal of natural hormones by nanofiltration membranes: measurement, modeling, and mechanisms. Environ. Sci. Technol. 2004, 38:1888-1896.
28. Nghiem L.D., Shaefer A.I., Elimelech M. Role of electrostatic interactions in the retention of pharmaceutically active contaminants by a loose nanofiltration membrane. J.Membr. Sci. 2006, 286:52-59.
29. Pedrouzo M., Borrull F., Pocurull E., Marcé R. Presence of pharmaceuticals and hormones in waters from sewage treatment plants. Water. Air. Soil. Pollut. 2011, 217:267-281.
30. Radjenovic J., Petrovic M., Ventura F., Barcelò D. Rejection of pharmaceuticals in nanofiltration and reverse osmosis membrane drinking water treatment. Water Res. 2008, 42:3601-3610.
31. Rahimi M., Madaeni S.S., Abbasi K. CFD modeling of permeate flux in cross-flow microfiltration membrane. J.Membr. Sci. 2005, 255:23-31.
32. Röhricht M., Krisam J., Weise U., Kraus U.R., During R.A. Elimination of carbamazepine, diclofenac and naproxen from treated wastewater by nanofiltration. Clean- Soil Air Water 2009, 37:638-641.
33. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul. Toxicol. Pharmacol. 2004, 39:158-183.
34. Saravia F., Frimmel F.H. Role of NOM in the performance of adsorption-membrane hybrid systems applied for the removal of pharmaceuticals. Desalination 2008, 224:168-171.
35. Schäfer A.I., Ngheim L.D., Waite T.D. Removal of natural hormone estrone from secondary effluent and natural waters using membranes. Membrane Technology for Wastewater Technology and Reuse Conference. Tel Aviv 2001.
36. Schäfer A.I., Andritsos N., Karabelas A.J., Hoek E.M.V., Schneider R., Nyström M. Fouling in nanofiltration. Nanofiltration - Principles and Applications 2004, 169-239. Elsevier, (Chapter 20). A.I. Schäfer, T.D. Waite, A.G. Fane (Eds.).
37. Schaep J., Van der Bruggen B., Vandecasteele C., Wilms D. Influence of ion size and charge in nanofiltration. Separ. Purif. Technol. 1998, 14:155-162.
38. Snyder S.A., Adham S., Redding A.M., Cannon F.S., DeCarolis J., Oppenheimer J., Wert E.C., Yoon Y. Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals. Desalination 2007, 202:156-181.
39. Stackelberg P.E., Furlong E.T., Meyer M.T., Zaug S.D., Henderson A.K., Reissman D.B. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water treatment plant. Sci. Total Environ. 2004, 329:99-113.
40. Ternes T.A. Occurrence of drugs in german sewage treatment plants and rivers. Water Res. 1998, 32:3245-3260.
41. Ternes T.A., Meisenheimer M., Mc Dowell D., Bauch H.J., Haist-Gulde B., Preus G., Wilme U., Zulei-Seibert N. Removal of pharmaceuticals during drinking water treatment. Environ. Sci. Technol. 2002, 36:3855-3863.
42. Urase T., Sato K. The effect of deterioration of nanofiltration membrane on retention of pharmaceuticals. Desalination 2007, 202:385-391.
43. Van der Bruggen B., Braeken L., Vandecasteele C. Evaluation of parameters describing flux decline in nanofiltration of aqueous solutions containing organic compounds. Desalination 2002, 147:281-288.
44. Van der Bruggen B., Kim J.H., DiGiano F.A., Geens J., Vandecateele C. Influence of MF pretreatment on NF performance for aqueous solutions containing particles and an organic foulant. Sep. Purif. Technol. 2004, 36:203-213.
45. Vergili I., Barlas H. Removal of selected pharmaceutical compounds from water by an organic polymer resin. J.Sci. Ind. Res. India 2009, 68:417-425.
46. Verliefde A., Cornelissen E., Amy G., Van der Bruggen B., Van Dijk H. Priority organic micropollutants in water sources in Flanders and the Netherlands and assessment of removal possibilities with nanofiltration. Environ. Pollut. 2007, 146:281-289.
47. Verliefde A., Heijman S.G.J., Cornelissen E.R., Amy G., Van der Bruggen B., Van Dijk J.C. Influence of electrostatic interactions on the rejection with NF and assessment of the removal efficiency during NF/GAC treatment of pharmaceutically active compounds in surface water. Water Res. 2007, 41:3227-3240.
48. Verliefde A.R.D. Rejection of Organic Micropollutants by High Pressure Membranes (NF/RO) 2008, Water Management Academic Press, Netherlands.
49. Verliefde A.R.D., Cornelissen E.R., Heijmana S.G.J., Petrinic I., Luxbacher T., Amy G.L., Van der Bruggen B., Van Dijk J.C. Influence of membrane fouling by (pretreated) surface water on rejection of pharmaceutically active compounds (PhACs) by nanofiltration membranes. J.Membr. Sci. 2009, 330:90-103.
50. Vieno N.M., Härkki H., Tuhkanen T., Kronberg L. Occurrence of pharmaceuticals in river water and their elimination in a pilot-scale drinking water treatment plant. Environ. Sci. Technol. 2007, 41:5077-5084.
51. 2 and ozone. Water Res. 2004, 38:414-422.
52. Watts C., Maycock D., Crane M., Fawell J., Goslan E. Desk Based Review of Current Knowledge on Pharmaceuticals in Drinking Water and Estimation of Potential Levels - Final Report 2007, (Defra Project Code: CSA 7184/WT02046/DWI70/2/213).
53. Wei X., Wang Z., Fan F., Wang J., Wang S. Advanced treatment of a complex pharmaceutical wastewater by nanofiltration: membrane foulant identification and cleaning. Desalination 2010, 251:167-175.
54. Westerhoff P., Yoon Y., Snyder S., Wert E. Fate of endocrine disruptor, pharmaceutical, and personal care chemicals during simulated drinking water treatment processes. Environ. Sci. Technol. 2005, 39:6649-6663.
55. Yangali-Quintanilla V. Rejection of Emerging Organic Compounds by Nanofiltration and Reverse Osmosis Membranes: Effects of Fouling, Modeling and Water Reuse 2010, Delft University of Technology, Holland.
56. Yu Z., Peldszus S., Huck P.M. Adsorption characteristics of selected pharmaceuticals and an endocrine disrupting compound - Naproxen, carbamazepine and nonylphenol - on activated carbon. Water Res. 2008, 42:2873-2882.
57. Zazouli M.A., Susanto H., Nasseri S., Ulbricht M. Influences of solution chemistry and polymeric natural organic matter on the removal of aquatic pharmaceutical residuals by nanofiltration. Water Res. 2009, 43:3270-3280.
58. Zhang Y., Van der Bruggen B., Chen G.X., Braeken L., Vandecateele C. Removal of pesticides by nanofiltration: effect of the water matrix. Sep. Purif. Technol. 2004, 38:163-172.
59. Zwiener C. Occurrence and analysis of pharmaceuticals and their transformation products in drinking water treatment. Anal. Bioanal. Chem. 2007, 387:1159-1162.